Znn3bq.jpeg
²é¿´: 933  |  »Ø¸´: 2

chenlinana

Í­³æ (³õÈëÎÄ̳)

[ÇóÖú] ÇëÎʸßÊÖÕâ¾ä»°ÖÐtreat and extend regimenÓ¦¸ÃÔõô·­Ò룿

To evaluate the visual outcome, number of injections, and direct medical cost of a "treat and extend regimen (TER) in managing neovascular age-related macular degeneration (nAMD) with intravitreal ranibizumab.
ÇëÎʸßÊÖÕâ¾ä»°ÖÐtreat and extend regimenÓ¦¸ÃÔõô·­Ò룿

» ²ÂÄãϲ»¶

Î¢Ð¦Ãæ¶ÔÿһÌì
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

RXMCDM

°æÖ÷ (ÎÄ̳¾«Ó¢)

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

ÕÒµ½ÄÜ˵Ã÷Õâ¸ö´ÊµÄÎÄ×ÖÈçÏ£¬¾õµÃ¿ÉÒÔÃãÇ¿·­Îª¡¡¡¡ÖÎÁƼÁÁ¿¼°ÖÎÁƺóµÍƵ¸øÒ©¡¡¡¡¹©Äã²Î¿¼£¡
TREAT AND EXTEND¡± DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATION
Purpose: The purpose of this study was to analyze long-term outcomes for the treatment of type 3 neovascularization/retinal angiomatous proliferation using a ¡°Treat and Extend¡± dosing regimen for antivascular endothelial growth factor therapy.
Methods: This was a retrospective analysis of visual acuity and optical coherence tomography data of 11 eyes of 10 consecutive patients with newly diagnosed type 3 neovascularization/retinal angiomatous proliferation treated with intravitreal bevacizumab and/or ranibizumab with at least a 12-month follow-up. Three monthly injections were followed by continued treatment at intervals increasing by 2 weeks per visit, to a maximum of 10 weeks, unless clinical or optical coherence tomography evidence of persistent or recurrent fluid was present, in which case, the interval was shortened.
£¿
2Â¥2014-08-01 00:17:24
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

xux730

Ìú¸Ëľ³æ (ÖøÃûдÊÖ)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï
RXMCDM: ½ð±Ò+1, ¶àлӦÖú£¡ 2014-08-03 20:59:03
chenlinana(RXMCDM´ú·¢): ½ð±Ò+4, ¶àлӦÖú£¡ 2014-08-12 09:16:19
ÖÎÁƺÍÑÓÉì·½°¸£º³õ²½ÖÎÁƺó¼ÌÐø¸øÒ©£¬µ«ÊǸøÒ©µÄ¼äÆÚÖð½¥ÑÓ³¤¡£
3Â¥2014-08-01 02:56:21
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ chenlinana µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[»ù½ðÉêÇë] Óб¬ÁÏ£¬Ò»¸öÇàÄê½ÌʦÂô·¿µÃ400Íò£¬È»ºó»»ÁËÒ»¸öËÄÇàñ×Ó +9 babu2015 2026-04-08 9/450 2026-04-10 11:43 by ËÕ¶«ÆÂ¶þÊÀ
[¿¼ÑÐ] »úе»¹Óл¹ÓÐÃû¶îÂð£¿Ì«ÄÑÁË +5 ЦЦԬ 2026-04-10 5/250 2026-04-10 11:11 by zhouyuwinner
[¿¼ÑÐ] ²ÄÁÏÀà284µ÷¼Á +33 Ïë»»ÊÖ»ú²»Ïë½âÊ 2026-04-08 40/2000 2026-04-10 11:05 by Ccclqqq
[¿¼ÑÐ] 296Çóµ÷¼Á +6 Íô£¡£¿£¡ 2026-04-08 6/300 2026-04-10 11:02 by mattzhming
[¿¼ÑÐ] ¿¼Ñе÷¼Á +22 ˶ÐǸ° 2026-04-09 23/1150 2026-04-10 09:43 by liuhuiying09
[¿¼ÑÐ] 277 ÊýÒ»104£¬Ñ§Ë¶£¬Çóµ÷¼Á +14 Æ¿×ÓPZ 2026-04-09 15/750 2026-04-10 09:32 by grey499
[¿¼ÑÐ] ÉúÎïѧÇóµ÷¼Á Ò»Ö¾Ô¸»¦9£¬326·Ö +7 Áõīī 2026-04-06 7/350 2026-04-10 08:11 by kangsm
[¿¼ÑÐ] 0703»¯Ñ§Çóµ÷¼Á +21 ²»ÖªÃûµÄСئ 2026-04-08 21/1050 2026-04-09 18:55 by l_paradox
[¿¼ÑÐ] Ò»Ö¾Ô¸Öйú¿ÆÑ§ÔºÉϺ£ÓлúËù£¬Óлú»¯Ñ§356·ÖÕÒµ÷¼Á +11 Nadiums 2026-04-09 11/550 2026-04-09 18:04 by lijunpoly
[¿¼ÑÐ] ²ÄÁÏ299ר˶Çóµ÷¼Á +10 +21 2026-04-09 10/500 2026-04-09 17:34 by 1753564080
[¿¼ÑÐ] ²ÄÁÏ¿ÆÑ§Ó빤³Ì320Çóµ÷¼Á£¬080500 +12 »Æ¹ÏζÊíÆ¬ 2026-04-06 12/600 2026-04-08 16:26 by luoyongfeng
[¿¼²©] É격 +8 IQwQl 2026-04-04 8/400 2026-04-08 09:43 by 0608104024
[¿¼ÑÐ] 388Çóµ÷¼Á +6 ËÄ´¨ÍõÌÎ 2026-04-07 8/400 2026-04-08 00:17 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸¹þ¶û±õ¹¤Òµ´óѧ085600Ó¢Ò»Êý¶þ337·ÖÇóµ÷¼Á +12 lyz0427 2026-04-03 12/600 2026-04-06 06:37 by houyaoxu
[¿¼ÑÐ] Ò»Ö¾Ô¸±±¾©½»Í¨´óѧ²ÄÁϹ¤³Ì×Ü·Ö358Çóµ÷¼Á +4 cs0106 2026-04-04 4/200 2026-04-05 18:46 by imissbao
[¿¼ÑÐ] ¿¼Ñе÷¼Á +3 mcbbc 2026-04-04 3/150 2026-04-05 10:03 by barlinike
[¿¼ÑÐ] ÄÐÉú£¬Ò»Ö¾Ô¸»¦9ÉúÎïѧ071000£¬³õÊÔ308Çóµ÷¼Á +3 Áõīī 2026-04-04 3/150 2026-04-05 08:26 by barlinike
[¿¼ÑÐ] 085602µ÷¼Á ³õÊÔ×Ü·Ö335 +12 19123253302 2026-04-04 12/600 2026-04-05 08:08 by 544594351
[¿¼ÑÐ] ÔõôɾÌû×Ó°¡ +3 ·ìêØ1000 2026-04-04 3/150 2026-04-04 14:20 by ÍÁľ˶ʿÕÐÉú
[¿¼ÑÐ] Çóµ÷¼Á +3 ũҵ¹¤³ÌÓëÐÅÏ¢¼ 2026-04-04 3/150 2026-04-04 12:19 by Éá¶øºóµÃ
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û